#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Dermatitis atopic Asthma Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Myotonia Granulomatosis with polyangiitis Osteosarcoma metastatic Gastrointestinal neuroendocrine tumour Porphyria non-acute Peritoneal neoplasm Pancreatic neuroendocrine tumour Neovascular age-related macular degeneration Sickle cell disease Systemic mastocytosis Central nervous system lymphoma IPEX syndrome Extraskeletal ossification Leiomyosarcoma metastatic Short stature homeobox gene mutation More trials…

    Learn about Rare Diseases

    Small intestine leiomyosarcoma – Treatment Basal cell naevus syndrome Mantle cell lymphoma Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome Waldenstrom’s macroglobulinaemia recurrent – Diagnostics Behcet’s syndrome – Treatment Factor VIII deficiency – Treatment Urea cycle disorder – Diagnostics Congenital generalised lipodystrophy Wolfram syndrome – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Rezvilutamide Ampicillin Trimethoprim Maraviroc Bimatoprost Fenofibrate Paclitaxel Obaluronate Vobramitamab Duocarmazine Namodenoson AZD0022 Lomustine [Al[18F]F]Fapi-74 Favezelimab ATIRMOCICLIB Ucart20X22 Hydroxyzine Hydrochloride Belumosudil Mesilate Levodropropizine Ly3298176 XELAFASLATIDE More therapies…

    Learn about Your Condition

    Skin candida Acute coronary syndrome Adenomyosis Endometrial cancer stage III Primary myelofibrosis White matter lesion Gastrointestinal carcinoma Thrombolysis Mite allergy Neoplasm Migraine Endometrial cancer stage II Athetosis Substance use disorder Palpitations More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

ABM

  • Study of Pembrolizumab, Lenvatinib, and Belzutifan for Patients with Renal Cell Carcinoma

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • Quavonlimab
    • Favezelimab
    • Lenvatinib
    France Hungary The Netherlands Poland Spain

  • Study of Risankizumab vs. Placebo for Patients with Active Psoriatic Arthritis and Inadequate Response to DMARD Therapy

    Not recruiting

    3 1
    Investigated Drugs:
    • Risankizumab
    Belgium Bulgaria Croatia Czechia Denmark Estonia +11

  • Study on Brigatinib for Patients with ALK+ Non-Small Cell Lung Cancer

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Brigatinib
    Spain

  • Study on Tafasitamab and Lenalidomide with Standard Therapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma Patients

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Diffuse large B-cell lymphoma
    Investigated Drugs:
    • Vinorelbine
    • Betamethasone Sodium Phosphate
    • Cyclophosphamide
    Austria Czechia France Germany Hungary Ireland +5

  • Study on Long-Term Safety of Itepekimab for Patients with Chronic Obstructive Pulmonary Disease (COPD)

    Not recruiting

    3 1
    Investigated Drugs:
    • Itepekimab
    Bulgaria Czechia Denmark Estonia France Germany +12

  • Study on TAR-200 and Cetrelimab for High-Risk Bladder Cancer Patients Not Responding to BCG and Unable or Unwilling to Have Surgery

    Not recruiting

    2 1 1
    Investigated Drugs:
    • Cetrelimab
    • Gemcitabine Hydrochloride
    Belgium France Germany Greece Italy The Netherlands +2
Previous Page
1 … 1,688 1,689 1,690 1,691 1,692 … 1,695
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!